baber/WOPTO huggingface dataset:
Patent NZ-538822-A (NZ)
Title: Means to facilitate delivery of electronic documents into a postal network
Inventor: CRANITCH STEVEN PATRICK
IPC: B41L47/00
Filed: 2003-08-28
Abstract: An automated hybrid mail system/method (10) is provided which sends a graphic image file (17a) from the sender's terminal (14) directly into a postal network (26) via a remote printing facility (24). The system checks that the recipient's address is correctly located on the graphic image file (17a) before sending and (optionally) verifying the recipient's address and adding a correct Delivery Point ID and bar code. The client-side operations require no filling in of pre-defined fields or templates; any computer application that produces a printable application document (13) can be used. Preferably, a single-click or simple operation by the sender (11) can automatically send the application document (13) to be printed as a hardcopy document (25) and mailed to a recipient (12). The server-side (21) operations are automated. The system tracks the graphic image file (17a) throughout the process using a unique identification number (17b) allocated when the graphic image file (17a) is created on the sender's terminal (14).
Patent NZ-538873-A (NZ)
Title: Methods and apparatus for stress relief using multiple energy sources
Inventor: WALKER DONNA M
IPC: C21D10/00
Filed: 2003-08-01
Abstract: Methods are presented for modifying a physical property of a structure, such as reducing or relieving remaining internal stress, in which two or more energy types are concurrently applied to the structure to change the physical property of interest in an accelerated fashion. A first energy type is applied to the structure according to an operational setting, at least one of the operational setting and a time value derived from a first order rate relationship for the first energy type and from a first order rate relationship for a second energy type and according to a desired physical property value. The second energy type is applied to the structure at an energy level above an activation energy for the structure. The first and second energy processes are performed concurrently for at least the time value and the first order rate relationship for the first energy process relates application of the first energy type to the structure and a physical property of the structure. The first order rate relationship for the second energy process relates application of the second energy type to the structure and the physical property.
Patent NZ-540366-A (NZ)
Title: Substituted alkyl amido piperidines
Inventor: MARZABADI MOHAMMAD R
IPC: A61K31/497
Filed: 2004-01-06
Abstract: Disclosed is a compound of formula (I) wherein: each R1 is independently hydrogen; -F; -CI; -Br; -I; -CN; -NO2; straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C2-C7 alkenyl; C3-C7 cycloalkyl or C5-C7 cycloalkenyl; aryl; heteroaryl; -N(R5)2; -(CH2)mOR5; -COR5; -CO2 R5; -OCOR5; -CON(R5)2; -N(R5)COR5; -N(R5)CON(R5)2; -OCON(R5)2 or -N(R5)CO2R5; R2 and R3 together be -( CH2)p-; R4 is straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl, C3-C6 cycloalkyl, C1-C7 alkyl-C3-C5 cycloalkyl; -N(R5) 2 or -( CH2)mOR5; each R5 is independently hydrogen; aryl; heteroaryl or straight chained or branched C1-C7 alkyl, wherein the alkyl may be substituted with an aryl or heteroaryl; R6 is independently hydrogen; straight chained or branched C1-C7 alkyl; R7 is independently hydrogen; phenyl or straight chained or branched C1-C7 alkyl, wherein the alkyl may be substituted with a phenyl; X is independently CR1 or N, provided that if one X is N then the remaining X are CR1; and the remainder of the substituents are as described in the specification; or a pharmaceutically acceptable salt thereof. Also disclosed is the use of the above compound in the manufacture of medicament for treating an affective disorder, a urinary disorder or an eating disorder.
Patent NZ-540476-A (NZ)
Title: A membrane, a method and die means for manufacturing same
Inventor: ENGELBREKTSSON ANDERS
IPC: B29D99/00
Filed: 2004-01-09
Abstract: Disclosed is a method of manufacturing a membrane (1) from a blank (39) by a cure, which membrane comprises two rubber layers (40, 41) and a fabric-formed reinforcement layer (19), positioned between said rubber layers. In order to counteract and prevent respectively undesirable displacements of said reinforcement layer (19) membrane sections, which are movable in an application position, are manufactured according to the invention having a form, which deviates from the application form, and/or are exposed to stretching during the cure in order to within said membrane section bring about a displacement of said reinforcement layer (19) across a portion of at least one of said rubber layers (40, 41) and consequently a position, which deviates from the blank building up during the cure. The invention also relates to a membrane, manufactured according to this method as well as a mold tool designed to carry out said method and said manufacture of said membrane respectively.
Patent NZ-541473-A (NZ)
Title: Patient controlled drug administration device
Inventor: RAKE KENNETH WAYNE
IPC: A61M5/142
Filed: 2003-12-26
Abstract: A patient controlled liquid drug administration device (10) comprises a reciprocating pump (12) having an inlet connectable to a source of a pressurized liquid drug, and an outlet connectable to the patient. A clamp (38) rotates between closed and open positions respectively blocking and enabling pump outflow. A plunger (48) above the pump has an end contacting a movable wall (26) of the pump and is movable between raised and lowered positions. A button (50) above the plunger moves between extended and depressed positions, and has a ledge that engages the clamp when the button is moved to the depressed position and moves the clamp to its open position. A compression spring (52) is disposed between the plunger and the button. A spring catch (60) engages a detent in the button when the button is moved to its depressed position and holds the button there until released by a catch release (62) on the plunger that disengages the spring catch from the detent in the button when the plunger is moved to its lowered position. A removable tab permits easy, rapid priming of the pump by holding the clamp in its open position regardless of the position of the button, and by holding the button in its depressed position regardless of the position of the plunger.
Patent NZ-550179-A (NZ)
Title: Saddle tube for a bicycle frame circular at the top, oval at the bottom with a flat on the chain side
Inventor: SMOLIK HANS-CHRISTIAN
IPC: B62K19/00
Filed: 2005-04-15
Abstract: A saddle tube (18) for a bicycle frame (10) is disclosed. The saddle tube (18) has a circular cross-section at the saddle post end (20). At the bottom bracket end (22) of the saddle tube (18) it is wider across the frame (10) than in the longitudinal direction (24) of the frame (10). On the side of the saddle tube (18) facing the chain ring there is a flat portion to leave sufficient space for the chain and derailer levers. A saddle tube (18) of this construction is claimed to be of higher stiffness at the bottom bracket end (22) than a traditional saddle tube.
Patent NZ-553408-A (NZ)
Title: Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
Inventor: NEYTS JOHAN
IPC: A61K31/52
Filed: 2005-07-26
Abstract: Disclosed are imidazo[4,5-d]pyrimidine compounds of formula (A), wherein U is N and the remaining substituents are as defined in the specification, methods of preparation of said compounds and their uses in treating of viral infection such as HCV infection.
Patent NZ-564892-A (NZ)
Title: Methods of treatment, and diagnosis of epilepsy by detecting a D674G mutation in the SCN1A gene
Inventor: MULLEY JOHN CHARLES
IPC: C12N15/01
Filed: 2006-06-16
Abstract: Disclosed is a method for the diagnosis of severe myoclonic epilepsy of infancy (SMEI) in a patient. The disclosed method comprises: 1) testing for an alteration in the SCN1A gene in a sample obtained from the patient; and 2) if an alteration is identified, comparing said alteration to those listed in the specification. If said alteration encodes a D674G amino acid change, a diagnosis of SMEI in said patient is made. Also disclosed are nucleic acids, expression vectors, and polypeptides which encompass the D674G alteration.
Patent NZ-565075-A (NZ)
Title: PSMA antibody-drug conjugates
Inventor: MA DANGSHE
IPC: A61K47/48
Filed: 2006-06-20
Abstract: Provided is an antibody-drug conjugate comprising: an antibody or antigen-binding fragment thereof, which binds to prostate-specific membrane antigen (PSMA), with a specified antigen amino acid sequence, conjugated to monomethylauristatin norephedrine wherein the antibody-drug conjugate has a PC_3TM cell to C4-2 or LNCapTM cell selectivity of at least 250. The conjugate can be used to treat tumours.
Patent NZ-586377-A (NZ)
Title: Grid members for a suspended ceiling and methods of making same with adhesive applied between two layered web or flange portions
Inventor: FIELD GRAHAM KEITH
IPC: E04B9/06
Filed: 2009-01-07
Abstract: Grid members, namely a runner (10) and wall angle (not shown) for suspended ceiling grids, are disclosed. Certain embodiments of the runner and the wall angle have two web portions (28, 30) and at least one distinct indent portion (62) to define a space between the web portions. An adhesive (56) may be disposed within one or more of the indent portions (62) to adhere the two web portions (28, 30) to each other. Certain embodiments of the runner or wall angle have flange portions (32, 34) that may have indent portions as well. One or more of these indent portions may contain adhesive. Some embodiments of the runner or wall angle have overturned cap portions on the flange portions, and an adhesive may be placed between the overturned cap portions and upwardly facing surfaces of the flange portions.
Patent NZ-588655-A (NZ)
Title: Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
Inventor: MCNAIR LINDSAY
IPC: A61K31/7072
Filed: 2009-04-23
Abstract: Disclosed herein is the use of VX-950 or a pharmaceutically acceptable salt thereof in an amount of about 750 mg or in an amount of about 1125 mg for the manufacture of a medicament for co-administration with pegylated interferon and ribavirin to a P/R non-responsive patient infected with Hepatitis C virus.
Patent NZ-589420-A (NZ)
Title: Wind turbine having multiple axially aligned generators with a deformable transmission inbetween which reduces stress on the shaft
Inventor: CASAZZA MATTEO
IPC: F03D9/00
Filed: 2010-11-22
Abstract: Disclosed is a wind power turbine for generating electric energy. The turbine has a supporting structure; a nacelle; a blade assembly which rotates with respect to the nacelle; and first and second electric generators. The first and second generators respectively include a first and second stator which are substantially coaxial with each other. The first and second generators have respectively a first and second rotor fitted to the first and second stator to rotate about a first and second axis. The first rotor connects to the blade assembly. The wind power turbine has a deformable transmission assembly which connects the first rotor to the second rotor. The deformable transmission assembly is configured to allow variations in alignment of the first and the second axes so as to reduce the flexural stress transmitted between the rotors.
Patent NZ-589496-A (NZ)
Title: Processes and compounds for the preparation of normorphinans
Inventor: WANG PETER X
IPC: A61P25/00
Filed: 2009-05-21
Abstract: Disclosed herein is processes and intermediate compounds useful in the production of normorphinans and derivatives thereof, namely related to compounds of formula 21a, wherein the substituents are as defined within the specification. A process for the preparation of compound of formula 21 via hydrolysis of the compound of 21a is also disclosed. Further disclosed is a process for the preparation of a compound of formula 24.
Patent NZ-590041-A (NZ)
Title: Method of treating anxious major depressive disorder
Inventor: FREY JOSEPH
IPC: A61K31/495
Filed: 2009-05-19
Abstract: Disclosed is the use of a compound comprising 4-{ (3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl} -N,N-diethylbenzamide or enantiomer thereof, or pharmaceutically acceptable salt thereof, or mixture thereof in the manufacture of a medicament for the therapy of anxious major depressive disorder.
Patent NZ-591633-A (NZ)
Title: Combination gas vaccines and therapeutics
Inventor: MANETTI ANDREA
IPC: A61K39/09
Filed: 2009-09-17
Abstract: Disclosed are compositions useful for reducing the risk of, preventing, and/or treating S. pyogenes (GAS) infections which comprise combinations of GAS antigens, nucleic acid molecules encoding the antigens, or antibodies which specifically bind to the antigens. The compositions comprise: (a) a combination of three or more different Streptococcus. pyogenes (GAS) protein antigens selected from the group consisting of: (1) Spy0167 or a mutant Spy0167 protein having a hemolytic activity that is reduced by at least 50% relative to a wild-type Spy0167 protein, wherein said mutant Sp0167 protein comprises one or more amino acid substitutions or deletions at one or more amino acid positions selected from the group consisting of P427, W535, C530, A248, and D482 numbered according to the sequence set forth in SEQ ID NO: 107; (2) Spy0269; and (3) Spy0416 or a mutant Spy0416 protein having a proteolytic activity against interleukin-8 (IL-8) as determined by SDS-polyacrylamide gel electrophoresis or ELISA that is reduced by at least 50% relative to a wild-type Spy0416 protein, wherein said mutant Sp0416 protein comprises one or more amino acid substitutions or deletions at one or more amino acid positions selected from the group consisting of D151, H279, and 5617 numbered according to the sequence set forth in SEQ ID NO: 1; or (b) one or more nucleic acid molecules encoding the GAS protein antigens at (1), (2), and (3); or (c) three or more different antibodies, wherein each antibody selectively binds to a GAS protein antigen selected from the group consisting of (1), (2), and (3), wherein each GAS protein antigen is different and the antibodies do not cross-react with each other.
Patent NZ-592890-A (NZ)
Title: Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
Inventor: JENSEN MICHAEL RUGAARD
IPC: A61K31/436
Filed: 2009-11-25
Abstract: 592890 Disclosed is the use of a compound of formula (E) and an mTOR inhibitor in the manufacture of a medicament for treating a proliferative disease such as tumors, myelomas, leukaemia, angiogenesis, psoriasis, restenosis, sclerodermitis or fibrosis. An example of an mTOR inhibitor is everolimus and an example of a compound of formula (E) is (R)-2-amino-7-[2-(6-methoxy-pyridin-2-yl)-phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one.
Patent NZ-593837-A (NZ)
Title: Recombinantly modified plasmin
Inventor: NOVOKHATNY VALERY
IPC: C12N9/68
Filed: 2008-11-25
Abstract: Provided is a recombinant plasmin polypeptide, comprising (a) a single N-terminal kringle domain homologous to a kringle domain of native human plasminogen having , wherein the N-terminal kringle domain comprises comprising a defined amino acid sequence wherein the last four amino acid residues within the kringle domain are V, P, Q, and C; and (b) a C-terminal domain activation site and serine protease domain comprising a specified amino acid sequence and which is homologous to the corresponding domains in human plasminogen; and wherein the polypeptide binds to immobilized lysine. Further provided are corresponding nucleic acid sequences encoding the polypeptide, variants of the peptides and methods of making recombinant plasmin polypeptides with different N-termini produced by protease digestion.
Patent NZ-594533-A (NZ)
Title: Improved carrier
Inventor: WALKER BRENT MAITLAND
IPC: B65G17/20
Filed: 2011-08-25
Abstract: 594533 A gambrel stabiliser apparatus 1, comprises a gambrel stabiliser conveyor 4 defining an endless path, and at least one gambrel stabiliser 2. The stabiliser 2 includes a body 8 and a gambrel support member 9 configured to engage with a gambrel to restrict the orientation and freedom of movement of the gambrel. The gambrel stabiliser 2 is attached to the gambrel stabiliser conveyor 4 such that the gambrel stabiliser 2 is conveyed about the endless path. The stabiliser prevents spinning and twisting of the carcase carried by the stabiliser.
Patent NZ-597198-A (NZ)
Title: 4-(3-butynyl)aminopyrimidine derivatives as pest control agents for agricultural and horticultural use
Inventor: SAKAI MASAAKI
IPC: A01N43/54
Filed: 2010-07-15
Abstract: Novel 4-(3-butynyl)aminopyrimidine derivatives represented by general formula [I] are useful as pest control agents. In general formula [I], R1 is a mono- or bi-cyclic ring which may contain 0 to 3 heteroatoms, for example, phenyl or oxazolyl; R2 is a hydrogen atom, -R, -OR, -C(O)OR, -C(O)NHR, -CONR2 (wherein R is straight-chain or branched C1-8 alkyl, or the like), hydroxyalkyl, or the like; R3 is a hydrogen atom, a halogen atom, acyloxy represented by (straight-chain or branched C1-8 aliphatic hydrocarbon group)-CO-O-, or the like; and R4 is a hydrogen atom, a halogen atom, C1-6 alkyl, or the like, or alternatively, R4 and R3 together with the carbon atoms on the pyrimidine ring may form a thiophene ring, a pyrrole ring, an imidazole ring, a benzene ring, a pyrimidine ring, a furan ring, a pyrazine ring, or a pyrrolidine ring.
Patent NZ-603791-A (NZ)
Title: Recovery of non-coagulated product in red meat fat reduction processes
Inventor: LUDVIGSEN BENT
IPC: A23L13/60
Filed: 2010-06-09
Abstract: 603791 Disclosed is a method for producing a defatted meat production comprising the steps of: heating ground fatty meat tissue to a temperature below the coagulation temperature of the fatty meat tissue, adding water or steam to the fatty meat tissue, separating the fatty meat tissue in a liquefied fat-containing portion and a defatted meat portion, recovering an aqueous phase from the liquefied fat-containing portion, and adding the aqueous phase to the defatted meat portion, wherein the aqueous phase is concentrated by removal of water prior to the addition to the defatted meat portion. The method increases the functionality of the defatted meat product and incorporates essential proteins and flavours in the final defatted meat product.
Patent NZ-607724-A (NZ)
Title: Topical medicament for treating or preventing pain
Inventor: GORMAN PETER
IPC: A61P43/00
Filed: 2008-07-11
Abstract: Disclosed is the use of 5 to 35 per cent of at least one soluble salt of a biologically acceptable alkali metal or alkaline earth metal and a pharmaceutically acceptable carrier in the manufacture of a topical medicament for treating or preventing pain; wherein the topical medicament is in the form of a cream, lotion, ointment, liniment, gel, poultice, cold or hot compress, dressing or plaster cast, and wherein the at least one soluble salt is sea salt which is soluble in an aqueous solution, is obtained by evaporating sea water and which contains predominantly sodium chloride.
Patent NZ-609493-A (NZ)
Title: Diagnosis and treatments relating to th2 inhibition
Inventor: ARRON JOSEPH R
IPC: G01N33/53
Filed: 2011-12-16
Abstract: Disclosed is a kit for detecting Total Periostin in a biological sample obtained from an asthma patient for stratifying/classifying asthma patients into likely responders and non-responders for therapeutic treatment with a TH2 Pathway Inhibitor wherein the kit comprises an antibody that binds to Total Periostin, which includes at least isoforms 1, 2, 3, and 4 of periostin.
Patent NZ-613161-A (NZ)
Title: Pouch, method of manufacturing a pouch and a method of dispensing a product from a pouch
Inventor: ULSTAD DAVID CARL
IPC: B65D81/32
Filed: 2011-12-09
Abstract: Disclosed is a single use pouch with a pouring spout dispenser, is made from a single web for storing fluid or liquid product. The pouch allows sterile storage and easier manufacturing along with reduced residual product remaining in the pouch once used. The single-use pouch comprises a web folded to form a pouch having a front panel, a back panel, a top edge, a bottom edge, and two side edges. The top edge, the bottom edge and one of the two side edges are sealed while the other of the two side edges is a fold line, and the front panel and the back panel define an interior space A liquid human milk fortifier product is contained in the interior space. The interior space includes a body and a spout, one side of the spout defined by the fold line, and the spout in fluid communication with the body and through which the product is dispensed from the pouch. The fold line acts as a channel to guide liquid product from the body towards an opening at the end of the spout. A width of the pouch is at least three times a width of the spout. The interior space includes a transition portion connecting the spout and the body, wherein the transition portion defines a travel path for the liquid product, and the travel path is at an angle to the fold line. At least one of the front panel and the rear panel includes a line of weakness positioned between the top edge and the body, and in a path transverse to the spout. A gripping portion is positioned between the top edge and the body. The gripping portion includes a portion of the front panel sealed to a portion of the back panel. At least one of the front panel and the rear panel includes a line of weakness positioned entirely within the gripping portion.
Patent NZ-614852-A (NZ)
Title: Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid
Inventor: BETANCOURT AIMESTHER
IPC: C07D401/06
Filed: 2012-02-14
Abstract: Disclosed is a stable composition comprising amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid ([5-Fluoro-2-methyl-3-(2-quinolinylmethyl)-1H-indol-1-yl]acetic acid) (OC000459) or a pharmaceutically acceptable salt thereof and a polymer selected from polyvinylpyrrolidone (PVP), a polyvinylpyrrolidone-vinylacetate copolymer (PVP-VA), hydroxypropylmethylcellulose (HPMC) and hypromellose-acetate-succinate (HPMCAS) and mixtures thereof. Also disclosed are methods for the synthesis of this amorphous form and its use in the treatment of conditions such as asthma, COPD, dermatitis, infection and multiple sclerosis.
Patent NZ-615225-A (NZ)
Title: Methods of producing biofuels, chlorophylls and carotenoids
Inventor: KALE ANIKET
IPC: C12P7/64
Filed: 2012-03-02
Abstract: Disclose a method of isolating chlorophylls and omega-3 rich oil from algae, comprising: a. dewatering substantially intact algal cells to make an algal biomass; b. adding a first ethanol fraction to the algal biomass in a ratio of about 1 part ethanol to about 1 part algal biomass by weight; c. separating a first substantially solid biomass fraction from a first substantially liquid fraction comprising proteins; d. combining the first substantially solid biomass fraction with a second ethanol fraction in a ratio of about 1 part ethanol to about 1 part solids by weight; e. separating a second substantially solid biomass fraction from a second substantially liquid fraction comprising polar lipids; f. combining the second substantially solid biomass fraction with a third ethanol solvent fraction in a ratio of about 1 part ethanol to about 1 part substantially solid biomass by weight; g. separating a third substantially solid biomass fraction from a third substantially liquid fraction comprising neutral lipids, including omega-3 fatty acids, carotenoids, and chlorophyll, wherein the third substantially solid biomass fraction comprises carbohydrates; and h. isolating at least one of carotenoids, chlorophyll, and omega-3 fatty acids from the third substantially liquid fraction.